Janet Roberts, Alan Herman & Assoc.
Eidogen-Sertanty and Specs Release Kinase-Targeted Library
San Diego, CA (September 6, 2005): Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, and Specs, a leading supplier of screening compounds and research chemicals, today announced the launch of a small molecule library focused toward inhibitors of several protein kinase families. This Kinase-Targeted Library represents the culmination of a co-marketing and collaborative service agreement between Eidogen-Sertanty and Specs.
Eidogen-Sertanty applied the Kinase Knowledgebase and eScreen. components of its DirectDesign discovery platform to select a subset of molecules from Specs' diverse compound collection. These selected molecules were predicted to have good bioavailability and activity against a series of therapeutically relevant kinases.
A subset of the Kinase-Targeted Library was experimentally validated through screening conducted at Memorial Sloan-Kettering Cancer Center against several of its in-house targets. Through Eidogen-Sertantys in silico eScreen activity assessment and prioritization process, it was found that only a small percentage of compounds needed to be screened to observe a 5-fold increase in hit rate relative to the original primary screening data. 'The eScreen data was overwhelmingly surprising to us, especially with respect to the observed enrichment in potential kinase inhibitors, which would have been missed otherwise.' commented Dr. Hakim Djaballah, Head of Screening at Memorial Sloan Kettering Cancer Center in New York.
Under the terms of the co-marketing agreement, Specs will distribute the Kinase-Targeted Library to its worldwide customer base of pharmaceutical and biotechnology companies.
To inquire about purchasing the Specs/Eidogen-Sertanty Kinase-Targeted library, please contact Specs at firstname.lastname@example.org.
Specs is one of the world's leading suppliers of chemistry solutions for drug discovery to the Life Science industry. The main activities of Specs are focused on the supply of large numbers of high-quality screening compounds for High Throughput Screening (HTS), on-site and/or off-site compound handling, cheminformatics and contract research for lead discovery programs. Equipped with state-of-the-art technology and world-class expertise, Specs provides custom-tailored services and breakthrough solutions, allowing the customers to concentrate on the development of their core (research) activities. Information about Specs can be found at www.specs.net.
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty.s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com.
# # #
Eidogen-Sertanty, the Eidogen-Sertanty logo, DirectDesign, and Kinase Knowledgebase, are trademarks of Eidogen-Sertanty, Inc. eScreen is a registered trademark of Eidogen-Sertanty. All other trademarks in this release are the property of their respective owners.